Abstract
Patients with myelofibrosis (MF) who discontinue ruxolitinib due to progression/resistance have poor prognoses. JAK inhibitors control symptoms and reduce spleen volumes with limited impact on underlying disease pathophysiology. Murine double minute 2 (MDM2), a negative regulator of p53, is overexpressed in circulating malignant CD34+ MF cells. The oral MDM2 inhibitor navtemadlin (KRT-232) restores p53 activity to drive apoptosis of wild-type TP53 tumor cells by inducing expression of pro-apoptotic Bcl-2 family proteins. Navtemadlin demonstrated promising clinical and disease-modifying activity and acceptable safety in a phase II study in patients with relapsed/refractory MF. The randomized phase III BOREAS study compares the efficacy and safety of navtemadlin to best available therapy in patients with MF that is relapsed/refractory to JAK inhibitor treatment. .
Original language | English (US) |
---|---|
Pages (from-to) | 4059-4069 |
Number of pages | 11 |
Journal | Future Oncology |
Volume | 18 |
Issue number | 37 |
DOIs | |
State | Published - Dec 1 2022 |
Keywords
- MDM2 inhibitor
- myelofibrosis
- myeloproliferative neoplasms
- navtemadlin
- p53
ASJC Scopus subject areas
- Oncology
- Cancer Research